Hypoxia signaling: Challenges and opportunities for cancer therapy

被引：31
|
作者：
Ivan, Mircea [1 ,2 ]
Fishel, Melissa L. [3 ,4 ]
Tudoran, Oana M. [5 ]
Pollok, Karen E. [3 ]
Wu, Xue [6 ]
Smith, Paul J. [7 ]
机构：
[1] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA
[2] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN USA
[3] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN USA
[4] IU Simon Comprehens Canc Ctr, Dept Pharmacol & Toxicol, Indianapolis, IN USA
[5] Oncol Inst Prof Dr Ion Chiricuta, Cluj Napoca, Cluj, Romania
[6] Ohio State Univ, Columbus, OH USA
[7] Cardiff Univ, Sch Med, Cardiff, Wales
来源：
SEMINARS IN CANCER BIOLOGY | 2022年 / 85卷
关键词：
Hypoxia; HIF1; HIF2; HIF inhibitors; Hypoxia-activated prodrug; SMALL-MOLECULE INHIBITOR; ANTI-ANGIOGENIC THERAPY; DNA TOPOISOMERASE-II; CYTOCHROMES P450 CYP; RENAL-CELL CARCINOMA; INDUCIBLE FACTOR; ACTIVATED PRODRUG; N-OXIDE; HEPATOCELLULAR-CARCINOMA; PROLYL HYDROXYLASE;
D O I：
10.1016/j.semcancer.2021.10.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Hypoxia is arguably the first recognized cancer microenvironment hallmark and affects virtually all cellular populations present in tumors. During the past decades the complex adaptive cellular responses to oxygen deprivation have been largely elucidated, raising hope for new anti cancer agents. Despite undeniable preclinical progress, therapeutic targeting of tumor hypoxia is yet to transition from bench to bedside. This review focuses on new pharmacological agents that exploit tumor hypoxia or interfere with hypoxia signaling and discusses strategies to maximize their therapeutic impact.
引用
收藏
页码：185 / 195
页数：11
相关论文
共 50 条
  • [31] Opportunities and challenges for anti-CD73 cancer therapy
    Chen, Siqi
    Wang, Long
    Fan, Jie
    Dominguez, Donye
    Qin, Lei
    Zhang, Yi
    Zhang, Bin
    PURINERGIC SIGNALLING, 2014, 10 (04) : 722 - 722
  • [32] Cancer epigenetic therapy: recent advances, challenges, and emerging opportunities
    Vatapalli, Rajita
    Rossi, Alex P.
    Chan, Ho Man
    Zhang, Jingwen
    EPIGENOMICS, 2025, 17 (01) : 59 - 74
  • [33] Stem Cells as Target for Prostate cancer Therapy: Opportunities and Challenges
    Claudia Escudero-Lourdes
    Ildemar Alvarado-Morales
    Erik J. Tokar
    Stem Cell Reviews and Reports, 2022, 18 : 2833 - 2851
  • [34] Stem Cells as Target for Prostate cancer Therapy: Opportunities and Challenges
    Escudero-Lourdes, Claudia
    Alvarado-Morales, Ildemar
    Tokar, Erik J.
    STEM CELL REVIEWS AND REPORTS, 2022, 18 (08) : 2833 - 2851
  • [35] Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges
    Chen, Yuchen
    Liu, Xinran
    Li, Yangkai
    Quan, Chuntao
    Zheng, Ling
    Huang, Kun
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2018, 16 : 211 - 223
  • [36] Photodynamic therapy for prostate cancer: Recent advances, challenges and opportunities
    Xue, Qin
    Zhang, Jingliang
    Jiao, Jianhua
    Qin, Weijun
    Yang, Xiaojian
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [37] Challenges and Opportunities of Nanotechnology as Delivery Platform for Tocotrienols in Cancer Therapy
    Maniam, Geetha
    Mai, Chun-Wai
    Zulkefeli, Mohd
    Dufes, Christine
    Tan, Doryn Meam-Yee
    Fu, Ju-Yen
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [38] Biopolymer-Based Nanomedicine for Cancer Therapy: Opportunities and Challenges
    Wu, Xixi
    Xin, Yuan
    Zhang, Hengtong
    Quan, Liang
    Ao, Qiang
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2024, 19 : 7415 - 7471
  • [39] Advances in siRNA delivery approaches in cancer therapy: challenges and opportunities
    Houman Isazadeh
    Farshid Oruji
    Shima Shabani
    Javad Behroozi
    Hadi Nasiri
    Alireza Isazadeh
    Morteza Akbari
    Molecular Biology Reports, 2023, 50 : 9529 - 9543
  • [40] DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
    Jurkovicova, Dana
    Neophytou, Christiana M.
    Gasparovic, Ana Cipak
    Goncalves, Ana Cristina
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (23)
12345